By Fineline Cube TransThera Sciences (Nanjing), Inc. (HKG: 2617) announced that China’s National Medical Products Administration (NMPA) has approved its Phase 2 clinical trial evaluating TT-00973 tablets in combination with firmonertinib mesylate for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR-sensitive mutations.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Phase 2 Clinical Trial |
| Product | TT-00973 tablets + firmonertinib mesylate |
| Indication | Locally advanced or metastatic NSCLC with EGFR-sensitive mutations |
| Approval Date | 13 Jul 2026 |
| Next Steps | Initiate patient enrollment; evaluate safety and efficacy endpoints |
Drug Profile & Mechanism of Action
- Molecule: Novel dual AXL/FLT3 inhibitor (oral)
- Developer: Independently developed by TransThera
- Innovation: First-in-class dual inhibition of AXL and FLT3 pathways, potentially overcoming resistance mechanisms in EGFR-mutant NSCLC
- Intellectual Property: Global patents held by TransThera covering the compound and therapeutic use
Clinical Evidence – Phase I Trial
| Endpoint | Result (TT-00973) |
|---|---|
| Safety Profile | Well tolerated across dose cohorts |
| Maximum Tolerated Dose | Not reached at highest tested dose |
| Clinical Efficacy | Observed in subset of patients with solid tumors |
| Dose-Limiting Toxicities | Minimal; manageable adverse events |
The Phase 1 trial established the safety profile and preliminary efficacy signals that supported advancement to Phase 2 testing in the specific NSCLC population.
Strategic Collaboration
- Partner: Shanghai Allist Pharmaceuticals Co., Ltd.
- Agreement Type: Clinical collaboration and drug supply agreement
- Trial Design: Jointly conducted Phase 2 study of TT-00973 + firmonertinib mesylate
- Patient Population: Locally advanced or metastatic NSCLC with EGFR-sensitive mutations
- Future Plans: Potential Phase 3 trial based on Phase 2 results
This strategic alliance combines TransThera’s expertise in kinase inhibitor development with Allist’s experience in EGFR-targeted therapies, creating a complementary approach to address treatment resistance in NSCLC.
Market Impact & Outlook
- NSCLC Landscape: EGFR-mutant NSCLC represents approximately 40-50% of Asian NSCLC cases, with significant unmet need for patients who develop resistance to current EGFR inhibitors
- Competitive Advantage: The dual AXL/FLT3 inhibition mechanism may provide enhanced efficacy compared to monotherapy approaches by targeting multiple resistance pathways simultaneously
- Commercial Potential: Successful development could position the combination as a second-line option for EGFR-mutant NSCLC patients who progress on first-generation EGFR inhibitors
- Regulatory Pathway: Positive Phase 2 results would support accelerated approval discussions with NMPA and potential international regulatory filings
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and commercial expectations for TT-00973. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.-Fineline Info & Tech